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Abstract
Background. Activation of the thrombospondin-1 (TSP-
1)-TGF-β pathway by glucose and the relevance of TSP-1-
dependent activation of TGF-β for renal matrix expansion,
renal fibrosis and sclerosis have previously been demon-
strated by our group in in vivo and in vitro studies.
Design and methods. We investigated renal biopsies
(n = 40) and clinical data (n = 30) of patients with di-
abetic nephropathy. Ten kidneys without evidence of renal
disease served as controls. Glomerular and cortical expres-
sionofTSP-1,p-smad2/3,fibrosisandglomerularsclerosis
(PAS) were assessed by immunhistochemical staining and
related with clinical data.
Results. Glomerular (g) and cortical (c) TSP-1 were in-
creased during diabetic nephropathy (g: 2.62 ± 2.65; c:
4.5 ± 4.2) compared to controls (g: 0.67 ± 0.7; c: 1.5 ±
1.2).P-smad2/3wassignificantlyincreased(g:16.7±12.9;
c:148.7±92.8)comparedtocontrols(g:7.1±3.6;c:55±
25; P < 0.05). TSP-1 was coexpressed with p-smad2/3 as
an indicator of TGF-β activation. TSP-1 correlated with
enhanced tubulointerstitial p-smad2/3 positivity (r = 0.39
andr=0.4,P<0.05)andglomerularp-smad2/3correlated
with proteinuria (r = 0.35, P < 0.05).
Conclusions. In summary, the present study suggests a
functional activity of the TSP-1/TGF-β axis, especially in
thetubulointerstitiumofpatientswithdiabeticnephropathy.
Thepositivecorrelationofglomerularp-smad2/3positivity
withproteinuriafurthersupportstheimportanceoftheTSP-
1/TGF-β system as a relevant mechanism for progression
of human type-2 diabetic nephropathy.
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Introduction
Diabetic nephropathy is the number one cause of end-stage
renal failure in the western world [1]. Despite a steadily
increasing number of diabetic patients, there exist few con-
cepts to prevent disease progression and overt renal fail-
ure [2]. While predominant changes during early diabetic
nephropathy include altered haemodynamics, hyperfiltra-
tion and hyperglycaemia, progressive glomerulosclerosis
with the presence of Kimmelstiel–Wilson lesions and tubu-
lointerstitial fibrosis can be found during later stages of
disease [3,4].
TGF-β is considered the central cytokine for the de-
velopment of diabetic nephropathy mediating glomeru-
lar hypertrophy, matrix expansion and glomerulosclero-
sis [5]. After its extracellular activation, TGF-β binds
to the specific receptors TGF-β-R1 and -R2 mediat-
ing phosphorylation of transcription signalling molecules
(p-smads) and subsequent transcription of target genes
[6,7].
Thrombospondin-1 (TSP-1) is the founding member of
a family of matricellular glycoproteins [8]. While predomi-
nantly in vitro studies have assigned diverse functions such
as phagocytosis, adhesion, chemotaxis, proliferation and
migration of cells to TSP-1 [8–10], it has also been identi-
fied as an activator of the TGF-β-procytokine complex. In
vitro and in vivo studies by others [11,12] and our group
[13–15] have shown that TSP-1 binds to the latent TGF-
β-procytokine complex causing a conformational change
and acting as an endogenous activator of TGF-β in inflam-
matory disease. Since we recently established TSP-1 as an
endogenous activator of TGF-β in experimental diabetic
nephropathy in vivo [15], this study aimed to examine the
potential relevance of the TSP-1/TGF-β axis for human
type-2 diabetic nephropathy.
In the present study, we evaluated the spatial relation-
ship of glomerular as well tubulointerstitial expression of
TSP-1 and subsequent TGF-β signalling in biopsies from
patients with type-2 diabetic nephropathy and correlated
these biopsy data with each other and with clinical data of
disease progression.
C   The Author [2008].
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Table 1. Scoring system for the assessment of diabetic nephropathy
Parameter Grade 1 Grade 2 Grade 3
Glomerulosclerosis Mildly increased glomerular matrix and
sclerosis (up to 30%)
Moderate matrix expansion and
sclerosis (<50%)
Extensive matrix expansion,
Kimmelstiel–Wilson lesions,
global obliteration
Tubulointerstitial fibrosis Mildly increased tubulointerstitial matrix Increased matrix, initial tubular
atrophy widening of the
tubulointerstitium
Extensive matrix expansion and
tubular atrophy
Inflammation No relevant inflammatory reaction Inflammation in up to 50% of the
section
Severe inflammation in >50% of the
tissue section
Material and methods
Source of tissue
Archival tissues from core needle biopsies performed be-
tween 1992 and 2003 at the Klinikum Nuremberg (Nurem-
berg, Germany) were used for this study (n = 40). The
morphologicaldiagnosisofdiabeticnephropathywasmade
by the local pathologist unaware of study findings. Each
diagnosis was confirmed by the past medical history of
diabetes, thereby excluding patients with type 1 diabetes.
Control tissues without evidence of renal disease (n = 10)
were obtained from distant portions of kidneys surgically
excised because of the presence of a localized neoplasm.
Tissue processing and immunohistochemical staining
All biopsies were fixed in 3% paraformaldehyde, embed-
ded in paraffine, and cut into 4 µm sections for indirect
immunoperoxidase staining according to standard proto-
cols. Negative controls for immunostaining included either
deletion of the primary antibody or substitution of the pri-
mary antibody with equivalent concentrations of an irrele-
vant murine or rabbit mAb. Specific rabbit anti-mouse and
(allDakoCytomation, Hamburg,Germany) goatanti-rabbit
POD-conjugated(Dianova,Hamburg,Germany)secondary
antibodies were applied followed by colour development
with AEC (3-amino-9-ethylcarbazole; DakoCytomation), a
ready-to-use substrate chromogen.
To perform immunoperoxidase staining, tissue sections
were incubated with the following primary and secondary
antibodies as indicated at 4◦C overnight.
Antibodies used in this study
Antibodies used in this study were Clone A6.1, a murine
IgG1 mAbagainstTSP-1(Dunn,Asbach,Germany)[15];a
rabbitpolyclonalantibodyagainstphosphorylatedsmad2/3
(p-smad2/3) (Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA) [15] and a rabbit polyclonal antibody against
TGF-β1/2(SantaCruzBiotechnologyInc.)[15].PASstains
were used to evaluate glomerulosclerosis and tubulointer-
stitial fibrosis.
Quantitative analysis of immunostaining
For all stainings, all glomeruli were analysed in a blinded
fashion using a 400-fold magnification. Glomerular and
cortical TSP-1 were quantified using computer-assisted
image analysis software (MetaVue, Visitron Systems,
Puchheim, Germany) determining the percentage of area
positive for TSP-1. Glomerular and tubulointerstitial ex-
pression of TGF-β1/2 were evaluated using a semiquanti-
tative scoring system from 0 to 4, where 0 means <5%,
1 means 6–25%, 2 means 26–50%, 3 means 51–75% and
4 means 76–100% positively stained area per glomerular
cross section or tubulointerstitial field of vision, respec-
tively. Assessment of glomerulosclerosis was done via PAS
stainings. A semiquantitative scoring system from 0 to 4
was applied where 0 means no sclerosis and 1 means 0–
25%, 2 means 26–50%, 3 means 51–75% and 4 means 76–
100% of the glomerular tuft area is sclerotic. Fibrosis was
assessed on PAS-stained tissues using a semiquantitative
scoringsystemfrom0to3,where0meansabsenceoffibro-
sis, 1 means 0–25%, 2 means 26–50% and 3 means >50%
of fibrotic area. All findings were compared to glomeruli
from kidneys without evidence of renal disease. For every
biopsy the local nephropathologist evaluated the severity
of diabetic nephropathy in a blinded fashion. Thereby, each
biopsy was semiquantitatively graded according to the de-
gree of glomerulosclerosis, tubulointerstitial fibrosis and
inflammation from 1 to 3 as shown in Table 1 that de-
scribed the semiquantitative grade of morphology in dia-
betic nephropathy.
Immunohistochemical and fluorescence double staining
Double staining for TSP-1/p-smad2/3 was performed by
co-incubation of TSP-1 and p-smad2/3 antibodies followed
by different specific Alexa-Fluor antibodies.
Clinical records
At the day of biopsy the following data were collected from
the patients corresponding to their clinical record: age, du-
ration of diabetes, proteinuria, albuminuria, presence of
retinopathy, presence of diabetic neuropathy, presence du-
ration of hypertension, HbA1c level, serum creatinine and
urea.
Statistical analysis
All values were expressed as mean ± SD. Statistical
calculations were done using GraphPad Prism version
5.00 for Windows (GraphPad Software, San Diego, CA,
USA). In the first step all data were analysed using the3882 B. Hohenstein et al.
Kolmogorov–Smirnov test to test for normal distribution
of all parameters. For normally distributed data, statistical
significance (defined as a P-value of <0.05) was evalu-
ated using the unpaired t-test followed by an analysis of
variance (F-test) and in the case of statistically significant
differences regarding variances the Welch-test was used to
verify differences of data. For non-parametric testing, the
Mann–Whitney U-test was applied. Correlations were cal-
culated using Spearman’s algorithm.
Results
Glomerular and cortical TSP-1 as well as TGF-ß
expression are increased during diabetic nephropathy
In control kidneys, TSP-1 staining was absent in most
glomeruli (0.67 ± 0.68% positive area; Figure 1A) and
present only in small amounts predominantly in some
tubules within the tubulointerstitium (1.4 ± 1.2% posi-
tive area, Figure 1B). Glomerular (2.62 ± 2.65% posi-
tive area) as well as cortical (4.5 ± 4.2% positive area;
mainly consisting of tubulointerstitial) TSP-1 was in-
creased in diabetic versus control kidneys (both P < 0.05;
Figure 1C, D). Differentiation of diabetic nephropathy in
three stages of severity demonstrates that in milder dia-
betic lesions, glomerular and tubulointerstitial, an increase
of TSP-1 can be seen (stage 1: 1.98 ± 1.98, stage 2: 1.47 ±
1.94% positive area, Figure 1E–G), but did not reach sta-
tistical significance compared to controls due to the low
number of biopsies for these groups (stage 1: n = 5, stage
2: n = 5) and a significant variation of diabetic disease and
TSP-1 expression in individual glomeruli within the same
biopsy.Nevertheless,amongallbiopsies,glomerularTSP-1
expression correlated with disease stages (r = 0.392,
P < 0.05). In kidneys with enhanced diabetic disease,
glomeruli demonstrated most prominent TSP-1 expres-
sion in various cell types such as mesangial, endothe-
lial and inflammatory cells (stage 3: 3 ± 2.9% positive
area; Figure 1E, H–J), which reached statistical signifi-
cance (stage 3, n = 30, Figure 1E) compared to controls
(P < 0.05). In glomeruli with Kimmelstiel–Wilson lesions
(Figure1J),TSP-1expressioncouldbefoundattheexterior
oftheselesions,whiletheacellularnoduleswereusuallyde-
void of any TSP-1. In parallel, increased TSP-1 within the
cortex, predominantly reflecting tubulointerstitial expres-
sion, was most prominent in kidneys with advanced disease
(stage 1: 5.7 ± 4.4, stage 2: 3.9 ± 6.1, stage 3: 4.4 ±
3.9% positive area) compared to controls (1.49 ± 1.2
5% positive area, Figure 1F, P < 0.05) and could
be localized mainly to inflammatory cells and tubules
(Figure 1H).
In addition, we also evaluated TGF-β expression in a
smallerproportionofrenalbiopsies(normal:n=8,stage1:
n=4,stage2:n=0,stage3:n=8)toverifythepreviously
published increase of TGF-β during diabetic nephropathy
in this study [12,16]. Thereby we found significantly in-
creased glomerular [1.1 ± 0.28 (stage 1) and 1.54 ± 0.29
(stage 3) versus 0.55 ± 0.26; P < 0.05 and P < 0.001;
Figure 2A] and tubulointerstitial [1.38 ± 0.18 (stage 1) and
2.0 ± 0.53 (stage 3) versus 0.75 ± 0.27; P < 0.05 and
P < 0.001; Figure 2B] expression of TGF-β, as evaluated
after staining against TGF-β1/2.
Increased p-smad2/3 co-localizes and correlates with
TSP-1 expression during diabetic nephropathy
After activation of TGF-β,T G F - β receptor signalling led to
complexation of smads 2 and 3 and subsequent phospho-
rylation. Evaluation of p-smad2/3 positive nuclei showed
significantly increased positive cell numbers in glomeruli
(16. ± 12.9 versus 7.1 ± 3.6; P < 0.05) of biopsies with
diabetic nephropathy compared to controls (Figure 2C).
Hereby, glomerular numbers of p-smad2/3 positive nuclei
were similarly increased in all stages of diabetic glomeru-
lopathy (Figure 2D). In parallel, p-smad2/3 positivity was
increased threefold in the tubulointerstitium compared to
control biopsies (148 ± 92.8 versus 55 ± 25; P < 0.05,
Figure 2E) and this increase was relatively independent of
the stage of disease severity (Figure 2F).
To demonstrate that TSP-1 and p-smad2/3 co-localize
in biopsies with diabetic nephropathy, fluorescence double
labelling of TSP-1 and p-smad2/3 was performed. Thereby,
extracellular TSP-1 and nuclear p-smad2/3 clearly local-
ized next to each other in biopsies with type-2 diabetic
nephropathy.Examplesofco-localizationinglomerularand
tubulointerstitial diabetic lesions are depicted in Figure 2G
and H. Typical areas are shown as a zoomed image.
Activity of the tubulointerstitial TGF-β pathway correlates
with the degree of TSP-1 and proteinuria
After demonstration of co-localization of TSP-1 and
p-smad2/3, we subsequently assessed whether increased
TSP-1 expression is directly linked to increased TGF-β
activation as indicated by p-smad2/3. Hereby, both cor-
tical and glomerular TSP-1 expression correlated with the
amountofp-smad2/3positivecellsinthetubulointerstitium
(Figure 3A and B), while no correlation was detected
between glomerular TSP-1 and glomerular p-smad2/3.
Inthisstudy,clinicaldatafrom30outof40patientswere
available as shown in Table 2. The mean age of patients
was 59.35 ± 13.7 years (versus controls 48.9 ± 19.3 n.s.).
The mean duration of diabetes was 12.97 ± 8.8 years,
and proteinuria 5504 ± 5372 mg/24 h and albuminuria
2133 ± 2302 mg/24 h were markedly increased. In par-
allel, serum creatinine values (300.6 ± 114.9 µmol/l) in-
dicated advanced disease in most patients. A summary of
diabetes-associated complications is depicted in Table 2.
Sixty percent of all patients presented with a prior diagno-
sis of arterial hypertension and received antihypertensive
medication before the renal biopsy. Forty-three percent of
patients had been put on ACE inhibitor treatment prior to
the renal biopsy that had no influence on expression levels
of TSP-1 or p-smad2/3 compared to patients without ACE
inhibitors [TSP1 glomerular (%): 1.9 ± 1.1 versus 2.3 ±
1.2, n.s.; TSP-1 cortical (%): 3.1 ± 3.9 versus 3.4 ± 3.2,
n.s.; p-smad2/3 glomerular: 13.5 ± 8.8 versus 18.3 ± 10.4
(n), n.s.; p-smad2/3 cortical: 118.6 ± 55.9 versus 128.2 ±
53.9(n),n.s.].Differentiationofbaselinedatafromallthree
subgroups (grade 1–3) compared to controls demonstratesTSP-1 in human diabetic nephropathy 3883
Fig. 1. TSP-1 expression is enhanced during type-2 diabetic nephropathy. Immunohistochemistry of TSP-1 in normal kidneys demonstrated the wide
absence of TSP-1 in glomeruli (A) but some low level TSP-1 in tubules (B). Glomerular (C) and cortical (D; representing mainly tubulointerstitial)
TSP-1 expression were evaluated as described in the Material and methods section and were increased in type-2 diabetic nephropathy. Expression levels
of glomerular (E) and cortical (F) TSP-1 varied among biopsies with different severity of lesions. With ongoing disease (G) TSP-1 expression within
glomeruli could be detected in various glomerular and inflammatory cells (H, I). In the tubulointerstitium, TSP-1 was mainly confined to tubules
and inflammatory interstitial cells (G, H). Kimmelstiel–Wilson lesions demonstrated a typical staining pattern (J)( ∗P < 0.05 by the Mann–Whitney
U-test).3884 B. Hohenstein et al.
Fig. 2. Increased TGF-β expression and p-smad2/3 positivity during advanced diabetic nephropathy. Glomerular (A) and tubulointerstitial (B)i m -
munohistochemistry of TGF-β-1/2 were evaluated using a semiquantitative scoring system as described in the Material and methods section. Immuno-
histochemistry of p-smad2/3 was evaluated by counting positive cells in glomeruli and the tubulointerstitium. Glomerular p-smad2/3 was increased in
all diabetic biopsies (C) and biopsies with mild (grade 1) and advanced (grade 3) lesions (D) whereas cortical p-smad2/3 was increased in all subgroups
(E, F). Double labelling of TSP-1 and p-smad2/3 was performed as described in the Material and methods section (G, H). Panel G and its zoomed
areas depict glomerular co-localization; panel H depicts the clear co-localized TSP-1 and p-smad 2/3 in the tubulointerstitium of diabetic kidneys
(∗P < 0.05 by the Mann–Whitney U-test; #P < 0.05 by the unpaired t-test and Welch-test).TSP-1 in human diabetic nephropathy 3885
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Fig. 3. TSP-1 expression and p-smad2/3 positivity correlate in the tubulointerstitium. Correlations were calculated using Spearman’s algorithm.
Thereby, cortical TSP-1 (A) and glomerular TSP-1 (B) correlated with p-smad2/3 positivity in the tubulointerstitium. The number of glomerular cells
positive for p-smad2/3 also correlated with proteinuria in patients with diabetic nephropathy (C).
Table 2. Baseline parameters of diabetic and non-diabetic patients and
presence of diabetic complications
Parameter Diabetes group
mean ± SD or
%( n = 30)
Non-diabetic
controls mean
± SD (n = 10)
Age (years) 59.35 ± 13.7 48.9 ± 19.3
n.s.
Duration of diabetes (years) 12.97 ± 8.8 0
Proteinuria (mg/24 h) 5504 ± 5372∗ Not present
Albuminuria (mg/24 h) 2133 ± 2302∗ Not present
Patients on insulin therapy (n) 43% (n = 13) 0
Duration of insulin therapy (years) 7.6 ± 5.1 Not present
HbA1c level (mg/dl) 6.87 ± 1.97 Not present
Serum creatinine (mg/dl) 3.4 ± 1.3∗ 0.86 ± 0.28
Serum urea (mg/dl) 116 ± 37∗ 30 ± 10
Presence of hypertension (n) 63% (n = 19) 0
Duration of hypertension (years) 8.1 ± 9.2 0
Patients on ACE inhibitor 43% (n = 13) 0
therapy (n)
Prior history of stroke (n) 20% (n = 6) 0
Presence of coronary heart 46% (n = 14) 0
disease (n)
Presence of arterial occlusive 40% (n = 12) 0
disease (n)
Presence of retinopathy (n) 70% (n = 21) 0
Presence of diabetic 60% (n = 18) 0
neuropathy (n)
History of smoking (n) 63% (n = 19) Not present
n.s., not significant.
∗P < 0.05.
that functional parameters such as proteinuria and serum
creatinine are linked to severity of histological lesions
(glomerulosclerosis and fibrosis; Table 3).
We then correlated clinical parameters with the expres-
sionofTSP-1andp-smad2/3.Interestingly,beyondthecor-
relationofTSP-1withthediseasestage,theonlycorrelation
we detected was present between glomerular p-smad2/3
and the degree of proteinuria (Figure 3C). All other param-
eters assessed (age, glomerulosclerosis, fibrosis, duration
of diabetes, albuminuria, presence of retinopathy, presence
of diabetic neuropathy, presence duration of hypertension,
HbA1c level, serum creatinine and urea) did not show a
direct relationship to TSP-1 or p-smad2/3.
Discussion
Type-2 diabetes is one of the most challenging chronic
disorders in the western world [1]. After years of dia-
betes, diabetic nephropathy is very common and associated
with excess morbidity and mortality [2]. Despite some im-
proving grasp regarding the underlying pathophysiology,
treatment options after the onset of diabetic nephropathy
and chronic kidney disease are still very limited. Whereas
elevated blood glucose initially causes haemodynamic
alterations, hyperfiltration and activation of glomerular
cells [3], as well as excessive matrix deposition, are3886 B. Hohenstein et al.
Table 3. Baseline parameters in subgroups with diabetic nephropathy
Number of Age (years) Duration of HbA1c (%) Proteinuria Serum creatinine Fibrosis Glomerulo-
patients (n) diabetes (years) (g/24 h) (µmol/l) (scores 0–3) sclerosis
(scores 0–4)
Normal 10 48.9 ± 19.3 0 ± 0 n.a. n.a. 76 ± 26.5 0.5 ± 0.3 0.8 ± 0.3
Grade 1 (mild) 5 50.5 ± 23.2 8.6 ± 8.6 7.1 ± 2.4 0.81 ± 1.1 140.5 ± 35.4 1.6 ± 0.7 2.8 ± 0.8
Grade 2 5 60.0 ± 9.3 15.7 ± 4.6 8.15 ± 3.6 1.55 ± 1.2 92.8 ± 106.1 1.85 ± 0.4 3.5 ± 0.4
(moderate)
Grade 3 30 59.0 ± 13.5 13.5 ± 7.4 6.79 ± 1.7 9.3 ± 19.7 358.9 ± 247.5 2.4 ± 0.65 3.5 ± 0.38
(advanced)
n.a., data not available.
hallmarks of chronic diabetic nephropathy leading to
glomerulosclerosis and tubulointerstitial fibrosis of the
kidney [4]. TGF-β is the best-known profibrotic cy-
tokine, clearly being linked to the development of diabetic
nephropathy by various experimental studies [17]. To bind
to its receptors, latent TGF-β has to be extracellularly ac-
tivated. Our group recently demonstrated TSP-1 as an im-
portant endogenous activator of latent TGF-β in in vivo
and in vitro models of glomerulonephritis as well as di-
abetic nephropathy [13–15]. Therefore, interference with
the TGF-β activation process is an interesting therapeuti-
cal option to prevent its profibrotic action in the kidney
[13].
In the present biopsy study, we wanted to investigate
the relevance of the TSP-1/TGF-β axis in human biop-
sies with type-2 diabetic nephropathy. Dependent on the
severity of glomerular and tubulointerstitial lesions, the
local nephropathologist divided biopsies into three stages
(1–3) of diabetic nephropathy. Glomerular TSP-1 was in-
creased in biopsies with diabetic nephropathy, which was
most prominent in advanced disease in areas of glomeru-
losclerosis and fibrosis (stage 3). In parallel to this finding,
we also detected increased expression of TGF-β and of the
number of cells positive for the phosphorylated form of the
TGF-βsignallingcomplexsmad2/3inglomeruliofpatients
with diabetic nephropathy compared to controls. TSP-1
and p-smad2/3 were co-localized by fluorescence double
staining suggesting the experimentally shown functional
relationship [8]. Nevertheless, the degree of glomerular
TSP-1didnotdirectlycorrelatewiththeextent ofglomeru-
lar p-smad2/3 positivity, but did significantly correlate
with tubulointerstitial smad2/3 positivity. Although pure
speculation, this interesting link of glomerular TSP-1 with
tubulointerstitialTGF-βactivationmayindicateaparacrine
actionofTSP-1betweendifferentcompartmentsofthekid-
ney. Expression analysis of glomerular TSP-1 as well as
TGF-β and connective tissue growth factor (CTGF) has
been performed in a recent study by Wahab and colleagues
demonstratingin19biopsiesthatglomerularTSP-1,TGF-β
and CTGF are increased early on during human diabetic
nephropathy [12]. Our findings in 40 renal biopsies are
consistent with their data, showing increased glomerular
TSP-1 already in incipient diabetic lesions of our patients
andamorepronouncedincreaseinmoreseverediabeticdis-
ease. While this excellent study by Wahab and co-workers
[12] focused completely on glomerular changes, our study
also accounts for changes of the tubulointerstitium.
Hereby, we could demonstrate that cortical (reflecting
tubulointerstitial) TSP-1 was increased during diabetic
nephropathy and frequently co-localized with p-smad2/3
positivity indicating TGF-β signalling activity. In addition,
cortical TSP-1 correlated with the number of tubulointer-
stitial p-smad2/3 positive cells supporting the concept of a
causal relationship between TSP-1 and TGF-β activity in
human diabetic nephropathy. The importance of tubuloint-
erstitialchanges fortheoveralltimecourseandprogression
of human renal disease was established many years ago by
Bohle and co-workers [18], while more recent studies con-
firmed this also for the time course of diabetic nephropathy
[19,20]. Our group recently demonstrated in three differ-
ent experimental nephritis models with interstitial fibrosis
that TSP-1 co-localized with active TGF-β within the tubu-
lointerstitium and was an excellent predictor for the later
resulting interstitial fibrosis as detected in individual an-
imals [21]. Therefore, the results of this study suggest a
similar role for TSP-1 in human diabetic nephropathy.
Inaddition, correlatingalargenumber ofclinical param-
eters with the degree of glomerular p-smad2/3 positivity
or TSP-1, only the extent of glomerular p-smad2/3 posi-
tivity positively correlated with the degree of proteinuria
but no other clinical parameter as assessed in these dia-
betic patients. This interesting finding is consistent with
the reported direct relationship between urinary excretion
of TGF-β and proteinuria as well as TGF-β and glycaemic
control, at least early on in disease [22–24]. While we
detected a spatial and correlative relation between TSP-1
and the TGF-β activation, we did not find a correlation
of either factors with fibrosis/sclerosis in our biopsies from
patientswithdiabeticnephropathy.Whilethisseemstobea
surprisingresult,ithastobeconsideredthatdetectionofthe
profibrotic TGF-β activity might indicate/reflect active de
novo production of matrix molecules in a dynamic process
but not necessarily the general status of fibrosis, especially
when a given tissue is already quite fibrotic/sclerotic. In
our study, frequent acellular Kimmelstiel–Wilson lesions,
thedegreeoffibrosis/sclerosiswithinthesebiopsiesaswell
as the clinical data indicate mostly severe disease, where
the active component of matrix production may actually
already be slowed down.
In summary, the present study demonstrates the spatial
and suggests a functional activity of the TSP-1/TGF-β axis
in patients with type-2 diabetic nephropathy. Especially in
the tubulointerstitium of diabetic nephropathy, TSP-1 is
closely linked to TGF-β activity as indicated by p-smad2/3TSP-1 in human diabetic nephropathy 3887
positivity.Thepositivecorrelationofglomerularp-smad2/3
positivity with proteinuria further supports the importance
of the TSP-1/TGF-β system as a relevant mechanism for
progression of human type-2 diabetic nephropathy.
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